|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions</b>: Our data demonstrate that vitamin C kills thyroid cancer cells by inhibiting MAPK/ERK and PI3K/AKT pathways via a ROS-dependent mechanism and suggest that pharmaceutical concentration of vitamin C has potential clinical use in thyroid cancer therapy.
|
31285773 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a consequence, PI3K/AKT may be one of the key signalling pathways by which iodine promotes thyroid cancer development in association with SPANXA1.
|
31289536 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, LINC01296/miR-143-3p/MSI2 axis regulated development of TC through the AKT/STAT3 signaling pathway.
|
31693087 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the data of this study suggested that naringin presented anti-tumor effects in TC cells through inhibiting TC cell proliferation and inducing cell apoptosis via regulating the expression of cell proliferation and apoptosis related genes and PI3K/AKT pathway activation.
|
31727500 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that the protein abundance of OPN and its receptor, integrin β1, was highly increased and, concurrently, the downstream effectors AKT and NF-κB were significantly elevated to drive thyroid tumor progression of <i>Thrb<sup>PV/PV</sup>Pten<sup>+/-</sup></i> mice.
|
31392080 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, AXL stimulation with its ligand growth arrest-specific gene 6 (GAS6) increased AKT1- and p65 NF-kB-phosphorylation and promoted survival of thyroid cancer cell lines in culture.
|
31181609 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Under the influence of transcriptional regulators (such as Nuclear Factor-kappa B, mitogen-activated protein kinases, or Phosphoinositide-3 kinase/protein kinase-B), oncogenes connected to the different subtypes of TC promote their farthermost proliferative effect on the tumor microenvironment.
|
31158464 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer.
|
29353884 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PPFP thyroid cancers have increased activation of AKT, and mice with thyroid-specific expression of PPFP combined with thyroid-specific loss of PTEN (a negative regulator of AKT) develop thyroid cancer.
|
29420754 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blotting results indicated that sorafenib concurrently inhibited the activities of the MAPK and AKT/mTOR pathways in thyroid cancer.
|
29207150 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer.
|
27618325 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting AKT activity in the clinical setting may slow the growth and spread of aggressive thyroid neoplasms, and target the tumor stem cell compartment.
|
29169802 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular methods can also be applied as rule-out tests for malignancy in thyroid nodules, eg Afirma or ThyroSeq v2 or as markers of prognosis, eg TERT promoter mutation or other gene mutations including BRAF V600E, TP53 and AKT1, and as tests for newly defined tumour entities such as non-invasive follicular thyroid neoplasm with papillary like nuclei, or as a molecular marker(s) for targeted therapies.
|
29165888 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.
|
29262541 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, a thyroid cancer model using carcinogen and an anti-thyroidal agent revealed that Snx5<sup>-/-</sup> mice developed metastasizing thyroid tumors with activation of MAP kinase and AKT pathways, which are postulated to be major pathways of malignant progression of human thyroid carcinoma.
|
28771744 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to determine the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.<b>Experimental Design:</b> CUDC-907 is a first-in-class compound, functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway.
|
28600475 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to identify its expression, function, and molecular mechanism in thyroid cancer. microRNA-137 (miR-137) downregulation was observed in thyroid cancer tissues compared with normal thyroid tissues. miR-137 mimics downregulated B-CPAP cell proliferation, colony formation ability, and invasion, with suppressed expression of cyclin E, MMP2, p-ERK, and p-AKT. miR-137 inhibitor transfection in TPC-1 cell line showed the opposite effects.
|
26695142 |
2016 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the Shh pathway-stimulated thyroid tumor cell motility and invasiveness is largely mediated by AKT and c-Met activation with little involvement of EMT.
|
26859575 |
2016 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CHIP promotes thyroid cancer proliferation via activation of the MAPK and AKT pathways.
|
27342662 |
2016 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, expression of Sin1 and activation of AKT kinase were analyzed in fresh-frozen tissue samples (normal/tumor), primary cell cultures (papillary thyroid carcinoma [PTC]), and an established thyroid cancer cell line (medullary thyroid carcinoma) by Western blotting.
|
25456951 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroid cancer cells lose TSH/cAMP dependency of mTOR signaling and cell growth. mTOR activity is not decreased by the MEK or AKT inhibitors in the RAS or BRAF human thyroid cancer cell lines.
|
25029414 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro results suggest that the inhibition of either RAS-MAPK-ERK or PI3K-AKT-mTOR components may confer sensitivity of thyroid cancer cells to classic chemotherapeutics.
|
25016932 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other pathways like the PI3K/PTEN/AKT cascade are also active in many thyroid tumors.
|
24389136 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKT1 inhibitory DNAzymes inhibit cell proliferation and migration of thyroid cancer cells.
|
23725177 |
2013 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The genes, coding the signaling cascade proteins (e.g., RET, RAS, BRAF, PI3K, PTEN, AKT), are mutated or aberrantly expressed in thyroid cancer derived from follicular thyroid cell.
|
21196179 |
2011 |